This content is only available within our institutional offering.
26 Jul 2019
ROCHE: Increasing confidence in growth during the biosimilar phase | BUY - Top Picks | CHF340 vs. CHF332 (+29%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
ROCHE: Increasing confidence in growth during the biosimilar phase | BUY - Top Picks | CHF340 vs. CHF332 (+29%)
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
26 Jul 2019 -
Author:
Eric Le Berrigaud -
Pages:
3
ROCHE - BUY - Top Picks | CHF340 vs. CHF332 (+29%)
Increasing confidence in growth during the biosimilar phase
Dependence on soon-to-be-made-biosimilar drugs is decreasing
Far more to come over the next 18 months
The situation in the US remains the most significant overhang
Our numbers and FV adjusted upwards again